Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The potent effects of Japan's stem-cell policies.

Literature DB >> 31554988

The potent effects of Japan's stem-cell policies.

David Cyranoski.

Abstract

Keywords: Business; Ethics; Government; Stem cells

Mesh：

Year: 2019 PMID： 31554988 DOI： 10.1038/d41586-019-02847-3

Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962

× No keyword cloud information.

3 in total

1. Downgrading of regulation in regenerative medicine.

Authors: Douglas Sipp; Margaret Sleeboom-Faulkner
Journal: Science Date: 2019-08-16 Impact factor: 47.728

2. Japan responds: stem-cell therapy justified.

Authors: Shinji Miyamoto
Journal: Nature Date: 2019-05 Impact factor: 49.962

3. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study.

Authors: Kanako Tsuji; Yasuhiko Sakata; Kotaro Nochioka; Masanobu Miura; Takeshi Yamauchi; Takeo Onose; Ruri Abe; Takuya Oikawa; Shintaro Kasahara; Masayuki Sato; Takashi Shiroto; Jun Takahashi; Satoshi Miyata; Hiroaki Shimokawa
Journal: Eur J Heart Fail Date: 2017-03-31 Impact factor: 15.534

3 in total

4 in total

Review 1. Current regenerative medicine-based approaches for skin regeneration: A review of literature and a report on clinical applications in Japan.

Authors: Yusuke Shimizu; Edward Hosea Ntege; Hiroshi Sunami
Journal: Regen Ther Date: 2022-06-15 Impact factor: 3.651

The potent effects of Japan's stem-cell policies.

1. Downgrading of regulation in regenerative medicine.

2. Japan responds: stem-cell therapy justified.

3. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study.

Review 1. Current regenerative medicine-based approaches for skin regeneration: A review of literature and a report on clinical applications in Japan.

2. Financial risks posed by unproven cell interventions: Estimation of refunds from medical expense deductions in Japan.

3. A critical appraisal of Japan's new drug approval process: a case study of FLT3-ITD inhibitor quizartinib.

Review 4. Reflection on the enactment and impact of safety laws for regenerative medicine in Japan.